We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+6.58%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$333M
AUM Growth
+$77.5M
Cap. Flow
+$78M
Cap. Flow %
23.42%
Top 10 Hldgs %
35.62%
Holding
104
New
20
Increased
33
Reduced
37
Closed
13

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$11.1M
2
GILD icon
Gilead Sciences
GILD
+$11M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$9.82M
4
MDVN
MEDIVATION, INC.
MDVN
+$7.71M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.79M

Top Sells

Rank Stock Value
1
INVA icon
Innoviva
INVA
+$4.71M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$3.6M
3
ISRG icon
Intuitive Surgical
ISRG
+$3.07M
4
ZBH icon
Zimmer Biomet
ZBH
+$2.8M
5
AET
Aetna Inc
AET
+$2.74M

Sector Composition

Rank Sector Weight
1 Healthcare 79.75%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
26
Cigna
CI
$74.6B
$4.11M 1.23%
49,135
+22,135
+82% +$1.82M
AMGN icon
27
Amgen
AMGN
$222B
$3.95M 1.19%
+46,135
New +$5.6M
BSX icon
28
Boston Scientific
BSX
$71.5B
$3.85M 1.16%
284,978
+9,978
+4% +$131K
HCA icon
29
HCA Healthcare
HCA
$89.5B
$3.69M 1.11%
70,262
+15,262
+28% +$759K
CTRX
30
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
$3.62M 1.09%
+80,880
New +$3.89M
EW icon
31
Edwards Lifesciences
EW
$51.7B
$3.43M 1.03%
+277,122
New +$3.2M
AGN
32
DELISTED
Allergan Inc
AGN
$3.42M 1.03%
27,516
+2,516
+10% +$306K
NUVA
33
DELISTED
NuVasive, Inc.
NUVA
$3.4M 1.02%
+88,442
New +$3.25M
DXCM icon
34
DexCom
DXCM
$32B
$3.26M 0.98%
315,152
+7,152
+2% +$73.9K
COV
35
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$3.26M 0.98%
44,221
-779
-2% -$54.3K
BMY icon
36
Bristol-Myers Squibb
BMY
$132B
$3.18M 0.95%
86,815
+14,815
+21% +$788K
AEGR
37
DELISTED
Aegerion Pharmaceuticals
AEGR
$3.15M 0.95%
68,395
-6,605
-9% -$387K
LLY icon
38
Eli Lilly
LLY
$1.06T
$3.15M 0.94%
53,458
+18,458
+53% +$1.03M
CNC icon
39
Centene
CNC
$32.5B
$2.94M 0.88%
188,676
+48,676
+35% +$753K
UNH icon
40
UnitedHealth
UNH
$370B
$2.85M 0.86%
62,979
+18,979
+43% +$1.43M
ESRX
41
DELISTED
Express Scripts Holding Company
ESRX
$2.84M 0.85%
37,834
-27,166
-42% -$2.03M
PODD icon
42
Insulet
PODD
$9.79B
$2.8M 0.84%
58,961
-16,039
-21% -$710K
MCK icon
43
McKesson
MCK
$101B
$2.77M 0.83%
26,620
+13,620
+105% +$2.38M
CYH icon
44
Community Health Systems
CYH
$423M
$2.69M 0.81%
83,233
+28,783
+53% +$951K
LGND icon
45
Ligand Pharmaceuticals
LGND
$6.36B
$2.66M 0.8%
63,426
+2,512
+4% +$105K
PRXL
46
DELISTED
Parexel International Corp
PRXL
$2.66M 0.8%
49,135
-8,865
-15% -$454K
ELGX
47
DELISTED
Endologix Inc
ELGX
$2.6M 0.78%
20,184
+12,081
+149% +$1.88M
THOR
48
DELISTED
THORATEC CORPORATION
THOR
$2.46M 0.74%
68,788
-6,212
-8% -$223K
MDT icon
49
Medtronic
MDT
$112B
$2.43M 0.73%
39,429
-35,571
-47% -$2.07M
OCR
50
DELISTED
OMNICARE INC
OCR
$2.35M 0.7%
39,308
+2,308
+6% +$140K
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2014 Portfolio in Review

As of Q1 2014, Rhenman & Partners Asset Management held 104 positions worth $333M, up 30% from $256M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rhenman & Partners Asset Management deployed $78M of net new capital in Q1 2014, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Pfizer: 372,050 shares worth $11.3M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 83% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Ariad Pharmaceuticals Inc, an estimated $3.6M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2014 buy was Pfizer: 372,050 shares worth $11.3M.
  • Rhenman & Partners Asset Management added most to Gilead Sciences in Q1 2014, an estimated $11M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2014 reduction was Ariad Pharmaceuticals Inc, cutting an estimated $3.6M.
  • Rhenman & Partners Asset Management fully exited Innoviva in Q1 2014, selling an estimated $4.71M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 36% of its $333M portfolio in Q1 2014.
  • Rhenman & Partners Asset Management opened 20 new positions and closed 13 in Q1 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 30% quarter-over-quarter to $333M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2014, filed 14 May 2014.